References

Daratumumab: a review in combination therapy for transplant-ineligible newly diagnosed multiple myeloma

10.1007/s40265-019-01080-6 · 2019 · External reference

CD38 as an immunotherapeutic target in multiple myeloma

10.1080/14712598.2018.1544240 · 2018 · External reference

CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance

10.3389/fimmu.2018.02134 · 2018 · External reference

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

10.3390/cells9010167 · 2020 · External reference

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

10.1182/blood-2016-03-703439 · 2016 · External reference

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

10.1080/19420862.2015.1007813 · 2015 · External reference

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

10.1182/blood-2015-12-687749 · 2016 · External reference

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

10.1038/s41375-020-0810-4 · 2021 · External reference

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

10.1158/1078-0432.ccr-17-2027 · 2017 · External reference

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

10.3390/cells9020378 · 2020 · External reference

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients

10.3324/haematol.2019.219683 · 2020 · External reference

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

10.1038/leu.2015.123 · 2015 · External reference

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

10.1182/blood-2017-03-770776 · 2017 · External reference

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos

10.1182/blood-2018-05-850727 · 2018 · External reference

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

10.1182/blood.2019004332 · 2020 · External reference

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma

10.1038/s41375-019-0587-5 · 2020 · External reference

Efficacy and Safety of Daratumumab Combined With All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma

10.1182/bloodadvances.2021005220 · 2021 · External reference

Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

10.1038/s43018-019-0004-z · 2020 · External reference

A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma

10.1080/10428194.2022.2030476 · 2022 · External reference

Seeking convergence and cure with new myeloma therapies

10.1016/j.trecan.2018.05.005 · 2018 · External reference

CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma

10.1182/bloodadvances.2019001346 · 2020 · External reference

Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps

10.1038/nprot.2014.103 · 2014 · External reference

CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons

10.1016/j.neuron.2019.07.014 · 2019 · External reference

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma

10.1182/blood-2017-09-808063 · 2018 · External reference

PROMO: detection of known transcription regulatory elements using species-tailored searches

10.1093/bioinformatics/18.2.333 · 2002 · External reference

Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins

10.1038/nbt.1532 · 2009 · External reference

Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL

10.1158/2159-8290.cd-20-0242 · 2021 · External reference

Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma

10.1182/bloodadvances.2019000303 · 2019 · External reference

The MaxQuant computational platform for mass spectrometry-based shotgun proteomics

10.1038/nprot.2016.136 · 2016 · External reference

Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation

10.1016/j.cell.2014.09.029 · 2014 · External reference

MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens

10.1186/s13059-014-0554-4 · 2014 · External reference

Screening for inhibitors of an essential chromatin remodeler in mouse embryonic stem cells by monitoring transcriptional regulation

10.1177/1087057112455060 · 2012 · External reference

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

2016 · External reference

Hexim1, an RNA-controlled protein hub

10.1080/21541264.2018.1429836 · 2018 · External reference

Context-dependent regulation of Groucho/TLE-mediated repression

10.1016/j.gde.2008.07.010 · 2008 · External reference

A new age in functional genomics using CRISPR/Cas9 in arrayed library screening

10.3389/fgene.2015.00300 · 2015 · External reference

DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer

2013 · External reference

NF-kappaB dysregulation in multiple myeloma

2016 · External reference

Plasma cell differentiation requires the transcription factor XBP-1

10.1038/35085509 · 2001 · External reference

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

10.1182/blood-2006-09-044974 · 2007 · External reference

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

10.1038/nbt.1665 · 2010 · External reference

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma

10.1016/j.ccr.2013.08.009 · 2013 · External reference

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

10.1038/s43018-023-00657-1 · 2023 · External reference

CD38 as an immunomodulator in cancer

10.2217/fon-2020-0401 · 2020 · External reference

Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood

10.1016/j.stem.2007.10.001 · 2007 · External reference

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

10.1016/j.cell.2015.07.011 · 2015 · External reference

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

10.1016/j.cell.2015.07.056 · 2015 · External reference

Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II

10.1089/107999099313299 · 1999 · External reference

All-trans retinoic acid and interferon-alpha increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors

10.1038/bcj.2016.30 · 2016 · External reference

The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

10.1158/1078-0432.ccr-18-1597 · 2019 · External reference

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcgamma Receptor-Mediated Cross-Linking

10.4049/jimmunol.1501351 · 2016 · External reference

High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics

10.1038/nbt.3327 · 2015 · External reference

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells

10.1126/scisignal.2003573 · 2013 · External reference

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

10.1038/s41467-024-45561-z · 2024 · External reference

KDM6A Regulates Immune Response Genes in Multiple Myeloma

2024 · External reference

Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma

10.1182/blood-2011-07-366633 · 2012 · External reference

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma

10.1016/j.ccr.2007.07.003 · 2007 · External reference

FcepsilonRIgamma-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma

10.1182/bloodadvances.2020002440 · 2021 · External reference